leisure time -WSS

leisure time

author：knowledge 2025-09-06 04:14:33 - browse：11475

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Medical mystery: When a cough is not just a cough

WSS

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

With fresh data, a dynamic duo powers Eli Lilly to new heights

Private equity deals in Medicare Advantage declines

Why did Pfizer dish out millions for a Super Bowl ad?

Drinking water from half of US faucets contains PFAS: Study

What we’ve learned from the Aduhelm mess

leisure time

leisure time

explore

Jerome Adams on the need for new antivirals for Covid

To avoid data mishandling cases, universities eye AI and other tools

ChatGPT in medicine: STAT answers readers' burning questions

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

Guidelines to prevent youth baseball injuries need more muscle

What should King Charles tell the public about his cancer?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

To avoid data mishandling cases, universities eye AI and other tools

What does generative AI mean for health care? We asked experts

A disappointing year of Humira biosimilars

focus

Private equity deals in Medicare Advantage declines

BioAge raises $170M for combination therapy with Zepbound

Sen. Bill Cassidy on how to lower drug prices

PhRMA lawsuit over Medicare drug price negotiation tossed

What should King Charles tell the public about his cancer?

Robert F. Kennedy is pitching centrism on health, even on abortion

Wikipedia

leisure time

hotspot

entertainment